RxDoctor Payments Data

Carlo Honrado, MD

Facial Plastic Surgery · Los Angeles, CANPI 1437265980

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations.

$2,181in general payments, 2019–2025

Across 78 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$349
  • Stryker$346
  • Revance Therapeutics, Inc.$336
  • AbbVie$286
  • Merz North America, Inc.$231
  • Intersect ENT, Inc.$128
  • plus $505 from 10 others

What the payments were for

  • Food & beverage$2,181100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,181 in reported general payments places this provider in the 60th percentile of 120 facial plastic surgery providers in California.

See all facial plastic surgery providers in California

Medicare billing

Part B allowed, 2024
$73,456
Medicare patients
197
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide89$2,202
Azelastine Hcl66$1,762
Dexamethasone12$32

Paid to pharmacies, not to this prescriber.

Other facial plastic surgery in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →